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Utilization of HIV‑1 envelope V3
to identify X4‑ and R5‑specific Tat and LTR
sequence signatures
Gregory C. Antell1,2,3, Will Dampier1,2,3, Benjamas Aiamkitsumrit1,2, Michael R. Nonnemacher1,2,
Jeffrey M. Jacobson1,4,5, Vanessa Pirrone1,2, Wen Zhong1,2, Katherine Kercher1,2, Shendra Passic1,2,
Jean W. Williams1,2, Gregory Schwartz3, Uri Hershberg1,3, Fred C. Krebs1,2 and Brian Wigdahl1,2,6*

Abstract
Background: HIV-1 entry is a receptor-mediated process directed by the interaction of the viral envelope with the
host cell CD4 molecule and one of two co-receptors, CCR5 or CXCR4. The amino acid sequence of the third variable
(V3) loop of the HIV-1 envelope is highly predictive of co-receptor utilization preference during entry, and machine
learning predictive algorithms have been developed to characterize sequences as CCR5-utilizing (R5) or CXCR4utilizing (X4). It was hypothesized that while the V3 loop is predominantly responsible for determining co-receptor
binding, additional components of the HIV-1 genome may contribute to overall viral tropism and display sequence
signatures associated with co-receptor utilization.
Results: The accessory protein Tat and the HlV-1 long terminal repeat (LTR) were analyzed with respect to genetic
diversity and compared by Jensen–Shannon divergence which resulted in a correlation with both mean genetic
diversity as well as the absolute difference in genetic diversity between R5- and X4-genome specific trends. As
expected, the V3 domain of the gp120 protein was enriched with statistically divergent positions. Statistically divergent positions were also identified in Tat amino acid sequences within the transactivation and TAR-binding domains,
and in nucleotide positions throughout the LTR. We further analyzed LTR sequences for putative transcription factor
binding sites using the JASPAR transcription factor binding profile database and found several putative differences in
transcription factor binding sites between R5 and X4 HIV-1 genomes, specifically identifying the C/EBP sites I and II,
and Sp site III to differ with respect to sequence configuration for R5 and X4 LTRs.
Conclusion: These observations support the hypothesis that co-receptor utilization coincides with specific genetic
signatures in HIV-1 Tat and the LTR, likely due to differing transcriptional regulatory mechanisms and selective pressures applied within specific cellular targets during the course of productive HIV-1 infection.
Keywords: HIV-1, Co-receptor, Tropism, LTR, Tat, V3, gp120, Diversity, Divergence, Transcription factor
Background
HIV-1 entry is a receptor-mediated, pH-independent
process occurring via the direct interaction between
viral envelope glycoprotein (gp)120 and the host cell
CD4 receptor molecule, as well as one of the two most
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commonly encountered co-receptor molecules, CCR5
or CXCR4 [1]. The HIV-1 gp120 entry protein consists
of five variable regions (V1–V5), which are highly modified by insertion, deletion, and substitution mutations,
interspersed among five constant regions (C1–C5).
Regardless of this sequence hypervariability, the overall
structure and function of gp120 is highly conserved. Of
particular importance to the HIV-1 entry mechanism is
the third variable loop (V3), which has been shown to
consist of 34–36 amino acid residues (most commonly
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35 residues). The V3 domain has been extensively studied as it has been identified as the principal neutralizing
domain (PND) on the viral envelope gp120 [2–4] and the
viral partner in selective interactions with the different
co-receptors [5].
The V3 region is a major determinant in predicting
HIV-1 entry phenotype, distinguishing non-syncytium
inducing (NSI) from syncytium inducing (SI) strains and
macrophage tropic from non-macrophage tropic strains
[5–8]. In this regard, it was discovered that a T cell tropic
(T-tropic) isolate, or SI virus, preferentially uses the coreceptor CXCR4, and has consequently been referred to
as an X4 virus. In contrast, a primary macrophage tropic
(M-tropic) isolate, or NSI virus, was found to preferentially use the co-receptor CCR5 for entry and therefore
referred to as an R5 virus [9, 10]. Previously, viral tropism
based on co-receptor usage was used interchangeably
with tropism defined by cellular target; however, several
studies have shown that while co-receptor usage can
at times be linked with cellular tropism, it is important
to discuss viral infection in terms of utilization of a coreceptor in conjunction with the phenotype of the target
cell [11, 12]. As an example, recent investigations have
shown that HIV-1 infectious molecular clones containing transmitted/founder (T/F) genome sequences preferentially utilized CCR5 as a co-receptor during entry and
were able to replicate efficiently in primary CD4+ T cells
[13, 14]. These molecular clones also exhibited reduced
replication efficiency in monocyte-derived macrophages
(MDMs), in contrast to the prototypic M-tropic strains of
HIV-1 [13].
For high-throughput applications, co-receptor utilization predictions can be performed on Env-V3 sequences
computationally [15, 16]. To this end, the internet-based
bioinformatic method, position-specific scoring matrices
(Web-PSSM), utilizes sequences of known entry phenotype to determine if an Env-V3 sequence is CCR5- or
CXCR4-utilizing (R5 or X4 Env-V3 sequences). This
algorithm indicates the propensity of the virus to utilize
CXCR4 at both high sensitivity (84 %) and specificity
(96 %), with X4 virus sequences exhibiting high scores
and R5 sequences exhibiting low scores, while intermediate Web-PSSM scores indicates both R5 and X4 virus
sequences as well as dual tropic X4/R5 virus sequences
[17]. Typically, X4 viruses emerge gradually in a subset
of patients due to accumulation of amino acid changes
within the V3 loop, particularly at positions 11 and 25.
While HIV-1 co-receptor usage has been demonstrated
to be directly associated with the genotype of V3 loop,
as described above, other amino acid residues within
gp120 V1, V2, C4, and a number of regions of gp41, have
also been associated with co-receptor usage [18–27]. As
conformational changes within the V3 loop occur upon
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the binding of gp120 and CD4, it is possible that the coreceptor usage-associated amino acid residues within
other regions of envelope participate in the structural
rearrangement of gp120 [28].
The overall goal of this study was to identify and
characterize genetic differences between CCR5- and
CXCR4-utilizing HIV-1 sequences beyond the V3 loop
of envelope as defined by genotypic prediction. Specifically, HIV-1 gp120 and Tat amino acid sequences and the
HIV-1 long terminal repeat (LTR) nucleotide sequences
were selected for this analysis. The HIV-1 Tat protein
derives its name from the fact that its primary function
during viral replication is to serve as the trans-activator
of transcription. While not directly involved in HIV-1
entry, Tat has a multitude of intracellular host binding partners and functions. The HIV-1 LTR contains an
abundance of transcription factor binding sites upstream
of the transcription start site that alter levels of HIV-1
transcription, often in a cell type-dependent manner.
Importantly, these binding sites can work independently,
in concert, or antagonistically, with a single nucleotide
polymorphism capable of producing dramatic changes in
binding, including the complete abrogation of transcription factor binding [29, 30].
We hypothesized that co-evolved R5- or X4-associated
genetic signatures emerge in viral genes and proteins that
are not directly associated with entry, and suggest that
these differences are reflective of evolutionary constraints
applied by different cellular milieus that associate, coevolve, or co-adapt with co-receptor usage and may collectively guide tissue- and/or cell type-specific replication
patterns, as well as organ-specific disease pathogenesis.
The validity of this hypothesis is supported by the association of X4 virus with depleted CD4+ T-cell levels and
enhanced disease progression, as well as the tendency
of R5 virus to infect cells of the monocyte-macrophage
lineage and to be found at the time of transmission [31].
However, the full extent of the underlying changes in the
viral genome that could produce such a shift remains
unknown.
To remedy this, we have taken a genetic approach with
functional underpinnings that have centered on dividing HIV-1 co-linear sequences (gp120, Tat, and LTR)
into two co-receptor utilization groups using genotypic
prediction methods. Subsequently, we used these two
groups of sequences to explore the differences in the
remainder of gp120 sequences outside of Env-V3 as well
as co-linear Tat and LTR sequences (Table 1). Sequence
alignments of each co-receptor usage-defined population
of co-linear gp120, Tat, or LTR sequences were quantitatively evaluated at each amino acid (gp120 and Tat) or
nucleotide (LTR) position utilizing first-order diversity
and Jensen–Shannon divergence. Together, diversity and
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Table 1 Identification of HIV-1 Tat and LTR sequences colinear to CCR5- and CXCR4-utilizing Env-V3 sequences
defined by Web-PSSM scoring
Genomic region

CCR5

CXCR4

gp120

1678

52

Tat

504

31

LTR

615

35

HIV-1 amino acid sequences for gp120 and Tat and nucleotide sequences for
LTR were classified as being derived from CCR5- or CXCR4-utilizing genomes
according to Web-PSSM prediction scores utilizing the Env-V3 sequence.
Sequences with intermediate scores PSSM scores are derived from R5, X4, or
dual-tropic X4/R5 viruses and were not included in further analysis

divergence provide metrics to characterize the positionspecific variation of amino acids or nucleotides, as well as
provide a quantitative method to compare this information between R5- and X4-defined sequences. This strategy has provided a straightforward genetic approach to
define specific sequences in Tat and the LTR, or potentially any other HIV-1 sequence, that are co-selected with
CXCR4- and CCR5-dependent entry.

Results and discussion
Given the goal of this research was to determine if
genetic signatures co-evolved between different regions
of the HIV genome, it was first necessary to find patients
that had sequences from the genomic areas of interest.
From the Los Alamos National Library (LANL) database,
subtype B sequences derived from patient samples were
downloaded and aligned to the HXB2 genome. In total,
more than 2500 samples were isolated, which included a
full V3 of 35 amino-acids and at least one other co-linear
sequence in the Tat or LTR regions. This also included
1730 full gp120 sequences. Table 1 shows the breakdown
of sequences for each region and the selection criteria
are further described in the Methods. For all results discussed below, we have analyzed the diversity/divergence
of the amino acid sequences of gp120 and Tat proteins
while the nucleotides of the LTR have been analyzed.
Genetic diversity is correlated in R5‑ and X4‑classified
HIV‑1 gp120, Tat, and LTR sequence populations

Spearman’s rank correlation was performed to
assess the correlation between R5 and X4 diversity for gp120 (ρ = 0.8678, P = 2.00 × 10−156), Tat
(ρ = 0.8873, P = 4.67 × 10−35), and LTR (ρ = 0.7021,
P = 4.06 × 10−78) (Fig. 1). In all cases, R5 and X4 diversity
were well-correlated, with the P value indicating support
for the alternative hypothesis that X4 and R5 diversity is
unrelated. Because first-order diversity was utilized in
this analysis rather than richness (order = 0), and further
supported by rarefaction analysis of the sample sizes, it

Fig. 1 HIV-1 genetic diversity is highly correlated between corresponding positions in R5- and X4-classified gp120, Tat, and LTR
sequence populations. The genetic diversity (order = 1) of each
position of gp120, Tat, and LTR was calculated according to Eq. 1.
The positions were sorted across the x-axis according to the R5
diversity values (red line), with the corresponding X4 positions
plotted (blue dots). With this visualization, the vertical distance
between the line and the corresponding dot represents the difference in diversity between the R5- and X4-classified sequences at
each position. In general, the X4 values were found to cluster around
the R5 values, with a slight skew towards less diversity within the X4
population. Spearman’s rank correlation was performed to assess
the correlation between R5 and X4 diversity for gp120 (ρ = 0.8678,
P = 2.00 × 10−156), Tat (ρ = 0.8873, P = 4.67 × 10−35), and LTR
(ρ = 0.7021, P = 4.06 × 10−78). In all cases, R5 and X4 diversity were
well-correlated

is unlikely that differences in diversity are a reflection
of the differences in sample size between the R5 and X4
sequence groups. This result indicates that, in general,
corresponding amino acid (gp120 and Tat) or nucleotide
(LTR) positions are similarly constrained in their usage
with respect to R5 and X4 sequences.
Jensen–Shannon divergence correlates with differences
in diversity in HIV‑1 gp120, Tat, and LTR sequences

Notably, Jensen–Shannon divergence correlates well with
both mean diversity (ρ = 0.9226, 0.8552, and 0.9295 for
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gp120, Tat, and LTR, respectively) and the absolute difference in diversity (ρ = 0.9005, 0.8852, and 0.9685 for
gp120, Tat, and LTR, respectively) (Fig. 2). Together, these
observations indicate that the gain or loss of diversity
in one of the populations is closely associated with high
Jensen–Shannon divergence.
Amino acid diversity and Jensen–Shannon divergence
identified domains in gp120 responsible for CCR5 or
CXCR4 co‑receptor utilization

The HIV-1 envelope protein gp120 was evaluated to
detect the effectiveness of first-order sequence position
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diversity and Jensen–Shannon divergence with respect
to identifying genetic signatures of co-receptor utilization, with the expectation that the V3 domain exhibits
higher Jensen–Shannon divergence between R5- and
X4-associated gp120 sequences. Diversity analysis, which
as stated above was highly correlated between R5 (red)
and X4 (blue) sequence populations, confirmed that the
variable loops of gp120 display the greatest amount of
amino acid diversity (Fig. 3a). The V1 and V4 variable
domains, in particular, contain several positions that display diversity of greater than 10 at order = 1, with a large
proportion of positions having a diversity >3. Calculation

Fig. 2 Jensen–Shannon divergence is correlated with both mean genetic diversity and the absolute difference in genetic diversity. The relationship
between Jensen–Shannon divergence and genetic diversity (order = 1) in HIV-1 gp120, Tat, and LTR sequences was evaluated using Spearman’s
rank correlation. Both the mean diversity of R5- and X4-classified sequences and the absolute difference between R5 and X4 diversity correlated
with Jensen–Shannon divergence. This result indicates that large divergence can be a reflection of not only increased amounts of information (as
indicated by high mean diversity), but also by the loss of information in one of the two groups (as indicated by the absolute difference in mean
diversity)

Antell et al. Retrovirology (2016) 13:32
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Fig. 4 V3 domain of gp120 is enriched with statistically divergent
positions. The 10 conserved and variable domains of gp120 were
evaluated to determine if any regions were enriched in statistically
divergent sites. A hypergeometric test was used to determine enrichment and depletion of statistically divergent positions, using the null
hypothesis of equal distribution amongst domains. The V3 loop was
identified as being highly enriched (P = 1.74 × 10−11), while the C1
domain (P = 3.03 × 10−4) and C2 domain (P = 1.28 × 10−4) were statistically depleted at P < 0.01 using a Benjamini–Hochberg multiple
testing correction
Fig. 3 HIV-1 gp120 demonstrates high Jensen–Shannon divergence
in regions with high genetic diversity. HIV-1 gp120 sequences were
classified as CCR5 (R5) (n = 1681) or CXCR4 (X4) (n = 52) according
to the predicted co-receptor usage of the V3 domain Web-PSSM
score [17]. a The diversity index at a Hill number of 1 was calculated
for each position for both R5 (red) and X4 (blue) gp120 amino acid
sequence populations. Diversity values range from 1 to greater
than 10, with the variable domains of gp120 displaying the greatest
diversity. b The Jensen–Shannon divergence between R5 and X4
gp120 sequence populations was computed for each amino acid
position and plotted with a diamond. Statistically divergent positions
(P < 0.01) were plotted in red. A Monte Carlo permutation test was
performed to iteratively group gp120 sequences into random groups
and calculate a distribution of expected Jensen–Shannon divergence
values. The full range of this distribution was plotted in light blue with
the interquartile range plotted in dark blue. The full range of divergence for randomly generated groups is in close agreement with the
combined diversity of the R5 and X4 populations

of Jensen–Shannon divergence between the R5 and X4
populations identified 92 statistically significant positions throughout gp120 (Fig. 3b). A hypergeometric
statistical test was used to determine if any domains of
gp120 were enriched in statistically divergent positions,
as opposed to the null hypothesis of equal distribution.
Overall, the variable domains were enriched in divergent positions when compared to the null model, while
the conserved domains were depleted, although the C3
and V5 domains were in slight opposition to this trend
(Fig. 4). Specifically, the V3 loop was very highly enriched
[log2(fold change) = 1.89, P = 1.74 × 10−11] while the C1

domain [log2(fold change) = −1.09, P = 3.03 × 10−4] and
C2 domain [log2(fold change) = −1.57, P = 1.28 × 10−4]
were statistically depleted at P < 0.01 using a Benjamini–Hochberg multiple testing correction. With the
understanding that gp120 and V3 behaved as expected
following the application of diversity and divergence in
this study, Tat and the LTR were investigated for similar signatures that may co-evolve with alterations in coreceptor utilization patterns exhibited by Env-V3.
X4 Tat sequences demonstrate purifying selection in amino
acid usage

In general, we observed an overall trend for Tat to have
higher amino acid diversity in the fifth and sixth domains
of both groups (Fig. 5a). When we considered Jensen–
Shannon divergence, positions 7, 23, 57, and 60 were
found to be statistically divergent and P < 0.01 when
accounting for multiple testing with the Benjamini–
Hochberg procedure (Fig. 5b). For all four divergent positions, the set of amino acids used in each population was
similar, both with regard to the amino acids observed
as well as the physiochemical properties of these amino
acids (Fig. 6; Table 2). In all cases, the amino acid diversity of the X4 population was less than the diversity of
the R5 population, demonstrating the qualitative trend
that a subset of major variants become further enriched
within the X4 population (Fig. 7). While there was no
adequate statistical methodology to test the significance
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Fig. 5 Jensen–Shannon divergence identifies positions of differential
amino acid usage between R5 and X4 HIV-1 Tat sequences. HIV-1 Tat
sequences were sorted into R5 (n = 504) and X4 (n = 31) populations according to the predicted co-receptor usage of the co-linear
V3 domain as determined by Web-PSSM score. a The diversity index
at order = 1 was calculated for each position for both R5 (red) and
X4 (blue) Tat sequence populations. The diversity index between R5
and X4 populations displayed high similarity at nearly all positions,
with the second half of Tat displaying higher diversity values overall
for both populations. b The Jensen–Shannon divergence between
R5 and X4 Tat sequences was computed for each amino acid position
and plotted with a diamond. Statistically divergent positions 7, 23, 57,
and 60 (P < 0.01) were plotted in red and consensus changes, positions 40 and 67, were plotted in yellow. A Monte Carlo permutation
test was performed to iteratively group Tat sequences into random
groups and calculate a distribution of expected Jensen–Shannon
divergence values. The full range of this distribution was plotted in
light blue with the interquartile range plotted in dark blue

of the difference in diversity at a single position, a Fisher’s
exact test was used to demonstrate the statistical enrichment of the consensus variants R7 (P = 0.00053), T23
(P = 0.0012), and Q60 (P = 0.0158) within the X4 group
that is not a reflection of differences in R5 and X4 group
sizes. In contrast, Tat variant R57 was not statistically
enriched in the X4 population (P = 0.17). Regardless, this
observation lends support to a mechanism in which the
HIV-1 Tat X4 genotype undergoes purifying selection in
concert with the change in V3 co-receptor usage from R5
to X4, whereas R5 Tat may be able to persist within a less
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Fig. 6 Statistically divergent positions between X4 and R5 HIV-1
Tat interchange amino acids for those with similar physiochemical properties. The amino acid usage in four HIV-1 Tat amino acid
positions (7, 23, 57, and 60) was plotted for both R5 and X4 groups
as a stacked bar chart representing the total genetic variation within
each population at the respective positions. Amino acids were color
coded according to physiochemical property using the following
scheme: positively charged (red), negatively charged (blue), polar
uncharged (purple), hydrophobic (green), and unclassified (glycine,
proline, and cysteine, yellow). The amino acid positions 7, 23, 57, and
60 were selected due to their statistically significant Jensen–Shannon
divergence

constrained sequence space that allows it to effectively
drive HIV-1 transcription in both T cells and MDMs and
perhaps other cell lineages.
The four Tat amino acid positions of interest are
located within domains responsible for transactivation,
cysteine-rich, TAR binding, and nuclear localization,
respectively (Fig. 5). In order to further evaluate the
amino acid usage of these positions, the relative abundance of each variant was plotted (Fig. 6). In both R5 and
X4 Tat, arginine is the most common variant at position
7, although R7 is much more conserved within the X4
population. Previous studies have shown that an R7G
substitution has only 93.9 ± 6.5 % of the transactivation
activity of R7 [32]. While this effect size is small, it may
contribute to differences in the transactivation activity between R5 and X4 HIV-1. Position 23 of Tat also
is likely to play an important role in robust transactivation. In our data set, threonine was the most common
variant observed at position 23, although asparagine was
a frequent variant in both the R5 (46 %) and X4 (16 %)
sequences. The T23N substitution has been shown to
increase transactivation of the HIV-1 LTR, as well as
binding to P-TEFb [33]. Accordingly, Tat N23 has been
suggested to confer an advantage to HIV-1 by compensating for deleterious Tat mutations and supporting the
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Table 2 HIV-1 R5 and X4 Tat amino acid usage
Position

AA

7

K

95

0.19

0

0.00

N

12

0.02

2

0.06

S

115

0.23

2

0.06

R

281

0.56

27

0.87

N

230

0.46

5

0.16

T

274

0.54

26

0.84

A

5

0.01

3

0.10

R

400

0.79

28

0.90

T

89

0.18

0

0.00

E

87

0.17

1

0.03

D

7

0.01

2

0.06

K

30

0.06

0

0.00

Q

242

0.48

22

0.71

P

35

0.07

5

0.16

R

86

0.17

0

0.00

23
57

60

R5 count

R5 %

X4 count

X4 %

The raw counts and relative abundance value of amino acids present in
statistically divergent Tat positions for both the R5 and X4 sequence groups (7,
23, 57 and 60)

Fig. 7 Statistically divergent Tat positions demonstrate reduced
diversity within X4-classified sequences. Within HIV-1 Tat, four amino
acid positions were identified as having statistically significant
Jensen–Shannon divergence: 7, 23, 57, and 60. In all four cases, it was
noted that X4-classified variants exhibited a lower overall genetic
diversity at an order of 1, largely due to the enhanced presence
of the most common variant in the X4 population. This pattern of
diminished diversity within X4 in comparison to R5 suggests that a
purifying selective force may be present, affecting a subset of HIV-1
Tat variants

replication of less fit drug-resistant or immune-evasive
quasispecies [33]. Furthermore, the enrichment of the
T23N substitution in the R5 Tat population may relate
to the ability of R5 HIV-1 to productively infect both T
cells and monocytes and the selection of R5 HIV-1 at
the time of transmission, as opposed to X4 HIV-1 which
lacks a strong association with monocyte infection and
is selected against at the time of transmission. The coselection and possible synergistic effect of these Tat variants remains an area of future investigation.

Predicted transcription factor binding sites have
statistically different binding affinity scores between X4
and R5 LTR sequences

Genetic diversity and Jensen–Shannon divergence analyses were performed on LTR nucleotide sequences. 518
nucleotide positions spanning the HIV-1 U3, R, and
U5 regions were evaluated. High levels of nucleotide
diversity were present throughout the entire LTR and
did not display a general pattern beyond being low, i.e.
more highly conserved, in the approximately 50 nucleotides immediately downstream of the transcription start
site that correspond to the TAR region of the LTR. This
observation translated to large numbers of statistically
significant Jensen–Shannon divergence scores (n = 48)
between the two populations (Fig. 8). A number of these
statistically divergent positions were identified at nucleotide positions within the core enhancer domain, the
region of the LTR spanning approximately 200 nucleotides upstream of the transcription start site, while a
high number of divergent positions were also identified
in the less well characterized modulatory domain further
upstream. Due to the high concentration of known transcription factor binding sites within the core enhancer
domain, this region of the LTR was the focus of further
analysis.
Binding of cellular transcription factors to the LTR has
been shown to be one of the most critical parts of the
viral life cycle with respect to acute infection but also in
controlling the initial phases of genomic activation from
latency. Throughout the HIV-1 LTR, eight well-known
transcription factor binding sites were evaluated to
determine if differential nucleotide usage exists between
R5 and X4 populations: C/EBP-II (HXB2 positions
281–289), ATF-CREB (330–337), C/EBP-I (338–349),
NF-κB-II (350–359), NF-κB-I (363–373), Sp-III (377–
386), Sp-II (388–398), and Sp-I (399–408). Additionally,
the TAR stem-loop region (HXB2 positions 454–518)
was similarly investigated for R5- and X4-associated
differences.
The difference in nucleotide usage within known
transcription factor binding sites was visualized using
two-sequence logos (Fig. 9). This visualization creates
a sequence logo for each transcription factor binding
site that indicates nucleotides that are enriched within
either the R5 or X4 populations, and scaled according
to the maximum difference in relative abundance, such
that nucleotides more frequently found in the R5 or X4
population are displayed on the bottom or top partition
of the two-sequence logo, respectively, while completely
conserved nucleotides are displayed in the middle. This
analysis demonstrated that the greatest relative abundance differences in nucleotide usage occurred within
sites C/EBP-I (54.7 %), C/EBP-II (34.8 %), and Sp-III
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Fig. 8 HIV-1 LTR demonstrates high divergence both upstream and
downstream of the transcription start site. HIV-1 long terminal repeat
(LTR) sequences were sorted into R5 (n = 615) and X4 (n = 35) populations according to the predicted co-receptor usage of the co-linear
V3 region. a The diversity index at order = 1 was calculated for each
position for both R5 (red) and X4 (blue) LTR sequence populations,
numbered according to the HXB2 reference sequence. b Following
the same approach applied for amino acid analysis, Jensen–Shannon
divergence between R5 and X4 LTR sequences was computed for
each nucleotide position and plotted. Statistically divergent positions
were plotted in red and identified throughout the LTR, both upstream
and downstream of the transcriptional start site and within transcription factor binding sites. A Monte Carlo permutation simulation was
performed to randomly group LTR sequences and calculate a distribution of expected Jensen–Shannon divergence values, with the full
range (light blue) and interquartile range (dark blue) of the distribution
plotted across each position of the LTR

(43.2 %), as well as in the TAR stem loop (31.1 %). In contrast, NF-κB-I (11.7 %), NF-κB-II (8.6 %), Sp-I (13.8 %),
Sp-II (23.8 %), and ATF-CREB (11.8 %) showed rather
modest differences between X4 and R5 in terms of nucleotide usage. Statistically divergent positions were identified within several of these transcription factor binding
sites (Fig. 8), specifically sites C/EBP-I (position 346), C/
EBP-II (positions 281 and 284), and Sp-III (position 384),
as well as position 477 of the TAR stem loop, in agreement with the maximal differences observed in the twosequence logos. Specifically, when comparing R5 to X4
sequences, the aforementioned positions demonstrated a
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Fig. 9 R5 and X4 LTR sequences demonstrate signature enriched
nucleotide variants in transcription factor binding. HIV-1 transcription
factors that have been confirmed in vitro, C/EBP-II (HXB2 positions
281–289), ATF-CREB (330–337), C/EBP-I (338–349), NF-κB-II (350–
359), NF-κB-I (363–373), Sp-III (377–386), Sp-II (388–398), and Sp-I
(399–408), as well as the TAR stem loop (454–518), were evaluated
to detect enrichment and depletion of nucleotide variants in R5 and
X4 sets of aligned LTR sequences using two sample logos. Enriched
nucleotides were plotted proportional to the difference between the
populations, with the sum of the most differential position plotted on
the vertical axis

propensity for an A-to-G (HXB2 position 346) mutation
within C/EBP-I, an A/C-to-G (HXB2 position 281) and a
T-to-C (HXB2 position 284) mutation within C/EBP-II,
and a G-to-A (HXB2 position 384) mutation within SpIII. Finally, a large T-to-C (HXB2 position 477) mutation
was observed within the bulge region of the TAR stem
loop. The bulge region plays a crucial role in Tat recruitment and binding to the transcription complex, raising
the possibility that X4 HIV-1 may contain a large subpopulation of genomes that have altered Tat recruitment
and binding relative to R5 HIV-1 [34].
Although R5- and X4-specific nucleotide positions
were identified throughout the LTR, it was not clear if
those changes would result in meaningful differences
between R5 and X4 in terms of transcription factor
binding affinity. In order to quantitatively evaluate the
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difference between R5 and X4 LTR sequence groups,
analysis was performed using the JASPAR database, a
collection of transcription factor DNA-binding preferences modeled as matrices [35, 36]. Each LTR sequence
was scanned for transcription factor binding sites by
scoring against position weight matrices (PWMs), which
were converted from JASPAR position frequency matrices (PFMs) downloaded from the JASPAR vertebrate
database for C/EBP, SP1, NF-κB, and CREB. Each score
was then compared to the maximum possible score of the
corresponding PWM in order to determine a percentile
score. Only binding sites with a mean percentile score
>0.30 in either the R5- or X4-classified LTR sequences
were considered for statistical analysis (Table 3). The distribution of R5- and X4-binding scores was statistically
compared using a Kolmogorov–Smirnov (KS) test to calculate a P value.
Using the JASPAR matrices, we were able to correctly
identify the locations of each of the eight known transcription factor binding sites within the LTR when using
a percentile scoring threshold of 0.3. At this threshold,
the JASPAR matrices for C/EBP, Sp1, and CREB also
identified several other potential novel binding locations
(Table 3). Statistical analysis identified differential binding scores between the R5 and X4 populations at sites
C/EBP-I, C/EBP-II, and Sp-III, but not at known transcription factor binding sites Sp-I or Sp-II (Table 3). This
result is in agreement with the positions identified using
Jensen–Shannon divergence. Additionally, novel putative Sp1 and C/EBP binding sites with differential R5/
X4 JAPSAR scores were noted at positions 223 and 150,
respectively.
Interestingly, the relative magnitude of R5 and X4
mean binding scores of C/EBP-I and -II were opposite
one another, with X4 LTRs having a greater mean binding score than R5 LTRs for C/EBP-I, whereas R5 LTRs
have a greater mean binding score for C/EBP II. The
novel putative C/EBP site followed the trend of C/EBP
site I, and had a greater mean score among X4 LTRs.
This relationship may be a compensatory effect by which
the diminished binding affinity of C/EBP II, as the virus
mutates from R5 to X4, leads to greater binding to C/
EBP I and perhaps other putative C/EBP sites. This overall trend is also reflected among Sp binding sites. As the
binding affinity of Sp-III diminishes in X4 virus when
compared to R5, a putative novel Sp site at position 223
gains enhanced binding affinity as indicated by JASPAR
scoring. Generally, Sp sites have been shown to be more
important for LTR-driven transcription in T lymphocytes
than cells of the monocyte-macrophage lineage [37]. Furthermore, transcription factor binding at Sp-III varies
with respect to the level of differentiation of monocytes
[38]. Overall, we find that LTR-driven transcription is
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modulated by proteins of the Sp family in a manner that
is specific to cell phenotype. As an important contrast,
CREB and NF-κB binding sites did not demonstrate a difference in overall binding affinity between the R5 and X4
groups, although the analysis identified all known binding sites in both R5 and X4 populations. This is likely due
to the fact that these sites have been shown to be essential for both T-lymphocyte and monocyte-macrophage
replication [39–42].

Conclusion
The V3 domain of the HIV-1 env gene evolves throughout the course of infection, often resulting in a switch
from an R5 to an X4 swarm. However, the characterization of R5 and X4 HIV-1 has not been defined beyond the
envelope, specifically with respect to the transcriptional
regulation of HIV-1. Our findings indicate that when
comparing X4 HIV-1 to R5 HIV-1 sequences, Tat amino
acids variants are more strictly selected at several key
positions and specific LTR nucleotide variants are preferentially present in X4 HIV-1 sequences when compared
to R5 HIV-1. One particular caveat of our analysis, and
any that involves historical sequence review, is our choice
of the functional annotation algorithm used in these
studies. While the specific results may differ to some
extent with the choice of computational tools used in a
given study, the overall finding that there is co-evolution
between gp120 and other regions of the HIV-1 genome
remains consistent. These results are significant because
they indicate that the transcriptional phenotype of HIV-1
may diverge with respect to co-receptor utilization.
Importantly, the HIV-1 amino acid positions identified
in Tat as different between X4 and R5 play roles in supporting robust transactivation, while the LTR nucleotide
mutations associated with X4 and R5 strains are found
within known and putative transcription factor binding
sites and may affect their occupancy and contributions
to the regulation of HIV-1 gene expression. We regard
the genetic variation between X4 and R5 HIV-1 Tat and
LTR sequences to be indicative of selection caused by
the differential intracellular environments of cells preferentially infected by X4 versus R5 HIV-1 quasispecies.
Consequently, the evolution of HIV-1 from an R5 to an
X4 swarm likely requires adaptation at the level of transcriptional control in addition to co-receptor binding and
entry.
Methods
HIV‑1 sequence collection

HIV-1 sequences containing the Env-V3 region in addition to a co-linear Tat or LTR were collected and annotated from the Los Alamos National Laboratory (LANL)
HIV Sequence Database as of October 2014, while
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Table 3 Predicted transcription factor binding sites in the HIV-1 LTR
Transcription
factor

JASPAR
matrix

C/EBP

MA0102.1-CEBPA

76

Reverse

4.55

4.06

0.3860

MA0102.2-CEBPA

79

Reverse

4.94

4.41

0.3860

MA0102.2-CEBPA

81

Forward

4.24

3.12

0.2304

MA0102.1-CEBPA

150

Reverse

5.16

3.39

<0.0001

MA0102.2-CEBPA

153

Reverse

6.35

4.58

<0.0001

MA0102.2-CEBPA

154

Forward

4.53

1.83

<0.0001

MA0102.1-CEBPA

197

Reverse

5.27

4.63

0.0092

MA0102.2-CEBPA

200

Reverse

4.33

4.34

0.0063

CREB

In vitro
confirmed

X4 mean
score

R5 mean
score

P value

C/EBP II

278

Reverse

5.84

6.29

0.0005

MA0102.2-CEBPA

C/EBP II

281

Reverse

5.26

5.70

0.0010

MA0102.3-CEBPA

C/EBP II

281

Forward

7.65

9.67

0.0008

MA0102.2-CEBPA

C/EBP I

342

Forward

5.26

4.65

<0.0001

173

Forward

4.74

3.93

0.1020

330

Forward

5.25

5.63

0.4547

410

Reverse

4.43

4.68

0.8684

MA0018.2-CREB1
ATF/CREB

MA0018.2-CREB1

Sp

Strand
direction

MA0102.1-CEBPA

MA0018.2-CREB1
NF-kB

HXB2
index

MA0105.1-NFKB1

NF-kB II

350

Forward

13.66

14.52

0.9605

MA0105.1-NFKB1

NF-kB II

350

Reverse

7.43

8.30

0.9605

MA0105.2-NFKB1

NF-kB II

350

Forward

6.67

7.41

0.9605

MA0105.3-NFKB1

NF-kB II

350

Forward

12.37

13.41

0.9722

MA0105.1-NFKB1

NF-kB II

351

Reverse

4.85

5.31

0.9813

MA0105.1-NFKB1

NF-kB I

363

Forward

6.18

6.77

0.8062

MA0105.2-NFKB1

NF-kB I

363

Forward

8.20

8.62

0.8062

MA0105.2-NFKB1

NF-kB I

363

Reverse

7.60

7.88

0.8345

MA0105.1-NFKB1

NF-kB I

364

Forward

14.55

14.35

1.0000

MA0105.1-NFKB1

NF-kB I

364

Reverse

8.33

8.26

1.0000

MA0105.2-NFKB1

NF-kB I

364

Forward

7.44

7.29

1.0000

MA0105.3-NFKB1

NF-kB I

364

Forward

15.66

15.15

0.8907

MA0105.1-NFKB1

NF-kB I

365

Reverse

5.34

5.15

1.0000

MA0105.2-NFKB1

NF-kB

504

Forward

6.09

6.46

0.9850

MA0105.2-NFKB1

NF-kB

504

Reverse

8.56

8.83

0.9881

MA0105.1-NFKB1

NF-kB

505

Reverse

6.01

6.30

0.9850

MA0079.2-SP1

98

Reverse

4.68

5.68

0.0093

MA0079.1-SP1

99

Forward

5.01

5.35

0.0093

MA0079.1-SP1

223

Forward

4.35

3.31

<0.0001

MA0079.1-SP1

224

Forward

4.57

2.05

<0.0001

MA0079.1-SP1

266

Reverse

4.36

3.37

0.1034
0.5696

MA0079.2-SP1

Sp-III

373

Reverse

5.30

5.86

MA0079.1-SP1

Sp-III

374

Forward

4.12

4.82

0.0755

MA0079.2-SP1

Sp-III

376

Reverse

5.22

6.46

<0.0001

MA0079.1-SP1

Sp-III

377

Forward

3.86

5.56

<0.0001

MA0079.2-SP1

Sp-III

382

Reverse

4.71

5.81

<0.0001

MA0079.2-SP1

Sp-II

387

Reverse

6.72

7.11

0.7894

MA0079.3-SP1

Sp-II

387

Reverse

10.11

10.46

0.6982

MA0079.1-SP1

Sp-II

388

Forward

5.78

6.14

0.2648

MA0079.2-SP1

Sp-II

392

Reverse

6.62

7.07

0.1179

MA0079.2-SP1

Sp-II

393

Reverse

5.51

6.81

0.0168

MA0079.1-SP1

Sp-I

398

Forward

4.35

4.35

0.6176

MA0079.2-SP1

Sp-I

398

Reverse

6.69

7.21

0.5383

MA0079.1-SP1

Sp-I

399

Forward

4.30

4.47

0.5539
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Table 3 continued
Transcription
factor

JASPAR
matrix

In vitro
confirmed

HXB2
index

Strand
direction

MA0079.2-SP1

Sp-I

400

Reverse

5.78

5.83

1.0000

479

Forward

5.21

5.02

0.9279

MA0079.1-SP1

X4 mean
score

R5 mean
score

P value

LTR sequences classified as either R5 or X4 based on their co-linear Env-V3 sequence were scanned for potential transcription factor binding sites. All binding sites
with a percentile score >0.3 in either of the two groups were included in this analysis. The overall score distribution of R5 and X4 binding sites was compared using a
KS-test, and multiple testing was accounted for using the Benjamini–Hochberg procedure. Statistically significant sites (P < 0.01) are highlighted in italics

additional sequences from the Drexel Medicine CNS
Research and AIDS Eradication Study (CARES) Cohort
were added to supplement the total number of sequences
publicly available. The Drexel Medicine CARES Cohort
is a subtype B patient cohort from Philadelphia, Pennsylvania and has been previously described [43–46]. The
sequences from the Drexel Medicine CARES Cohort
have been submitted to Genbank under BioProject
ID: PRJNA319822. To reduce the effect of regional and
subtype differences, the LANL database query was limited to include only subtype B sequences isolated from
North America. The query was further limited to a single
sequence per patient using the LANL query tool which
specifically excludes laboratory strain sequences or those
used for functional studies. Table 1 shows the breakdown
of sequences for each region.

(MUSCLE), (version 5.05) [48] utilizing default parameters; insertions relative to the reference were removed
to simplify the analysis. This pipeline resulted in R5- and
X4-associated and multiple sequence alignments for each
gp120, Tat, and LTR sequence (Table 1).

Co‑receptor usage classification

Diversity, D, weighs the abundance of all variants, p, at a
given position, i, in the protein. A window length, w, is
applied, with w = 1 used in order to independently assess
the diversity of each position within a multiple sequence
alignment. At an order, or Hill number, of q = 1, D does
not exist; however, the limit as q approaches 1 can be
computed as shown here.
Diversity at order = 1 calculates the effective number of species (amino acids or nucleotides) in a population while giving greater weight to neither rare nor
abundant species. The maximum possible diversity
is 20 for amino acid sequences (gp120 and Tat) and 4
for nucleotide sequences (LTR), with gaps regarded as
missing data. In general, positions of high structural or
functional importance are evolutionarily constrained
in their use of amino acids or nucleotides and therefore
demonstrate low diversity, while positions more permissive to variation in amino acid or nucleotide usage displayed higher genetic diversity [50]. Rarefaction curves
for each position were generated in order to ensure
that sufficient sample sizes existed for each comparison
being made.

The in silico co-receptor usage prediction tool WebPSSM was used to classify all sequences as CCR5- or
CXCR4-utilizing based on the score of the co-linear
Env-V3 amino acid sequence [17]. Numerous exclusion
methods were utilized to reduce noise introduced by
Web-PSSM predictions as discussed previously [47].
Sequences were excluded from the study if the V3 region
was not 35 amino acid residues in length, if the V3 percentile determined by Web-PSSM was greater than
0.95 (indicating that a given sequence may not be a V3
sequence), or if the V3 PSSM score was in the ‘indeterminate range’ (using scoring cutoffs of >−2.88 and <−6.96
for X4 and R5 Env-V3 sequences, respectively), which
was defined as a scoring range consisting of sequences
with R5 and/or X4 properties including sequences that
are dual tropic (X4/R5). Using these cutoffs, this predictor has an 84 % sensitivity and 96 % specificity indicating
its ability to detect X4 binding sequences and non-binding sequences, respectively [17]. This filtering method
allowed the genetic analysis to focus on sequences with
the highest confidence classification in the PSSM-derived
distribution, definitively signifying CCR5- or CXCR4utilizing Env-V3 sequences. Following classification as R5
or X4, the co-linear gp120, Tat, and LTR sequences were
aligned to the HXB2 reference sequence (K03455) using
Multiple Sequence Comparison by Log-Expectation

Genetic diversity and rarefaction

The diversity of each amino acid or nucleotide position
of the respective multiple sequence alignments was calculated using a window length, w, of 1 and an order of 1
[equivalent to exp(Shannon entropy with base e)] according to Eq. 1 [49].
First-order genetic diversity


Rw,p
�
�
�
piw,p ln piw,p 
Dw,p = exp−
(1)
i=1

Jensen–Shannon divergence

Jensen–Shannon divergence is a measure of the similarity between two probability distributions that can be
applied to profile-to-profile multiple sequence alignment
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comparisons, with the divergence score bound by 0
(similar) and 1 (dissimilar) [51, 52]. Multiple sequence
alignments (MSA) generated from R5- and X4-classified
sequence populations were used to generate position frequency matrices (PFMs). Each PFM contains the relative
abundance of each residue (amino acid or nucleotide) for
each position (N) of the multiple sequence alignment,
resulting in 20 × N or 4 × N matrices for amino acid or
nucleotide sequences, respectively. Residues that are not
present in any of the sequences at a particular position
of the MSA were represented with a pseudo-count of
1 × 10−7, equivalent to a relative abundance of 1 instance
per ten million sequences, which ranges from approximately 1 × 104-fold to 1 × 106-fold lower abundance
than being present in a single sequence. PFMs derived
from R5- and X4-classified sequences were used to calculate the Jensen–Shannon divergence between populations according to Eq. 2.
Jensen–Shannon divergence
 20

20
Q1a  2
Q2a
1  1
Qa log2 0 +
Qa log2 0
DJS =
(2)
2
Qa a=1
Qa
a=1
where

Q0a


1 1
=
Qa + Q2a
2

Jensen–Shannon divergence, DJS, is determined according to the abundance of each amino acid variant, Qa, in
populations 1 and 2, using an information theory-based
calculation. The value Q0 is calculated for each amino
acid variant, and a pseudo-count is utilized for amino
acid variants absent in both populations.
Statistically significant positions were identified by
applying a Monte Carlo permutation test, which randomly re-grouped the total pool of sequences into groups
of size M and N iteratively (n = 1000), where M and N
are equivalent to the number of sequences in the X4 and
R5 groups, and generated a probability density function
(PDF) of the Jensen–Shannon divergence values of the
randomized model using a Gaussian kernel density estimator implemented in SciPy. Numerical integration was
used to determine the probability of finding a random
value greater than or equal to the true Jensen–Shannon
divergence.
Statistical analysis

Statistical analysis was performed in custom IPython
Notebooks using the SciPy Python library (version
0.14.0). Spearman’s rank correlation coefficient was used
to evaluate the relationship between R5 and X4 diversity
(Fig. 1), as well as the relationship of Jensen–Shannon
divergence to mean genetic diversity and the absolute
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difference in genetic diversity (Fig. 2), respectively. gp120
domain enrichment analysis (Fig. 4) of statistically divergent positions utilized a hypergeometric test, with a null
hypothesis of equal distribution of divergent positions.
Enrichment of consensus amino acids within statistically
divergent Tat positions was performed using a Fisher’s
exact test (Fig. 6).
Two sequence logos

Experimentally validated transcription factor bindings
sites C/EBP-II (HXB2 positions 281–289), ATF-CREB
(330–337), C/EBP-I (338–349), NF-κB-II (350–359),
NF-κB-I (363–373), Sp-III (377–386), Sp-II (388–398),
and Sp-I (399–408), as well as the RNA stem loop (454–
518), were evaluated using Two Sample Logo [53]. Two
Sample Logo is a web-based application that calculates
and visualizes the differences between two sets of aligned
sequences. Each nucleotide was represented with a different color, and the height of the one-letter nucleotide code
was scaled according to the magnitude of the difference
in abundance of the nucleotide at a given position, with
the largest difference in each comparison represented by
the maximum height in the logo.
Identification of putative transcription binding sites

Position frequency matrices (PFMs) were downloaded
from the JASPAR redundant vertebrate database for C/
EBP, Sp, NFκB, and CREB. Each PFM was converted into
a position weight matrix (PWM) as previously described
[52]. Each LTR sequence was scanned along its entirety
to score every potential binding site using each of the
PWMs. Each score was then compared to the maximum
possible score for the PWM being used in order to determine a percentile score. Only binding sites with a mean
percentile score >0.30 in either the R5- or X4-classified
LTR sequences were considered for statistical analysis
(Table 3). Binding affinities as defined by PWM score
show a non-Gaussian distribution (data not shown). As
such, the Kolmogorov–Smirnov (KS) test was used to
compare affinities between different groups. The PWM
was applied to each LTR and then the R5 and X4 distributions were compared. The P values were adjusted using
the Benjamini–Hochberg procedure.
Authors’ contributions
GA, BA, WD, MN, UH and BW conceived and designed the study. GA, WD, BA,
GS, and UH designed and performed the bioinformatic and statistical analyses.
BW, MN, VP, JJ, KK, JW, WZ, BA, GA and SP managed the Drexel Medicine CARES
Cohort and/or obtained sequences from patient PBMC samples. GA, UH, MN,
FK, and BW prepared and designed the figures and drafted the manuscript. All
authors read and approved the final manuscript.
Author details
1
Department of Microbiology and Immunology, Drexel University College
of Medicine, Philadelphia, PA, USA. 2 Center for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious

Antell et al. Retrovirology (2016) 13:32

Disease, Drexel University College of Medicine, Philadelphia, PA, USA. 3 School
of Biomedical Engineering, Science, and Health Systems, Drexel University,
Philadelphia, PA, USA. 4 Division of Infectious Diseases and HIV Medicine,
Department of Medicine, Drexel University College of Medicine, Philadelphia,
PA, USA. 5 Center for Clinical and Translational Medicine, Institute for Molecular
Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA, USA. 6 Sidney Kimmel Cancer Center, Thomas Jefferson University,
Philadelphia, PA, USA.
Acknowledgements
We would like to thank all patients who are part of the Drexel Medicine CARES
Cohort. We would also like to thank the clinical staff within the Division of
Infectious Diseases and HIV Medicine and Center for Clinical and Translational
Medicine in the Institute for Molecular Medicine and Infectious Disease at
the Drexel University College of Medicine who are involved in recruitment,
enrollment, obtaining consent, obtaining clinical histories, venipuncture,
and delivery of peripheral blood to the research laboratories in the Center
for Molecular Virology and Translational Neuroscience in the Institute for
Molecular Medicine and Infectious Disease. These studies were funded in
part by the Public Health Service, National Institutes of Health, through grants
from the National Institute of Neurological Disorders and Stroke (NS32092
and NS46263, Dr. Brian Wigdahl, Principal Investigator; NS089435, Dr. Michael
R. Nonnemacher, Principal Investigator), the National Institute of Drug Abuse
(DA19807, Dr. Brian Wigdahl, Principal Investigator), National Institute of Mental Health Comprehensive NeuroAIDS Center (CNAC) (P30 MH-092177, Kamel
Khalili, PI; Brian Wigdahl, PI of the Drexel subcontract; Michael Nonnemacher,
PI, Developmental Grant), and under the Ruth L. Kirschstein National Research
Service Award 5T32MH079785 (Jay Rappaport, PI; Brian Wigdahl, PI of the
Drexel subcontract). The contents of the paper are solely the responsibility of
the authors and do not necessarily represent the official views of the NIH. Drs.
Michael Nonnemacher, Will Dampier, and Fred Krebs were also supported by
faculty development funds provided by the Department of Microbiology and
Immunology and the Institute for Molecular Medicine and Infectious Disease.

Page 13 of 14

7.
8.

9.
10.
11.
12.
13.

14.

15.
16.

17.

Competing interests
The authors declare that they have no competing interests.
Ethics statement
The Drexel University College of Medicine Institutional Review Board (IRB) has
approved this work under protocol 1201000748. All patient samples were collected under the auspices of this protocol through written consent. Dr. Brian
Wigdahl is PI of the IRB protocol.
Received: 1 December 2015 Accepted: 20 April 2016

18.
19.
20.

21.
References
1. Arrildt KT, Joseph SB, Swanstrom R. The HIV-1 env protein: a coat of many
colors. Curr HIV/AIDS Rep. 2012;9:52–63.
2. Sirois S, Sing T, Chou KC. HIV-1 gp120 V3 loop for structure-based drug
design. Curr Protein Pept Sci. 2005;6:413–22.
3. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT,
Rusche JR, Bolognesi DP, Putney SD, et al. Principal neutralizing domain
of the human immunodeficiency virus type 1 envelope protein. Proc Natl
Acad Sci USA. 1989;86:6768–72.
4. Goudsmit J, Debouck C, Meloen RH, Smit L, Bakker M, Asher DM, Wolff AV,
Gibbs CJ Jr, Gajdusek DC. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific
antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci
USA. 1988;85:4478–82.
5. Sharon M, Kessler N, Levy R, Zolla-Pazner S, Gorlach M, Anglister J.
Alternative conformations of HIV-1 V3 loops mimic beta hairpins
in chemokines, suggesting a mechanism for coreceptor selectivity.
Structure. 2003;11:225–36.
6. De Jong JJ, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal
requirements for the human immunodeficiency virus type 1 V3 domain
to support the syncytium-inducing phenotype: analysis by single amino
acid substitution. J Virol. 1992;66:6777–80.

22.
23.
24.

25.
26.

27.

Cormier EG, Dragic T. The crown and stem of the V3 loop play distinct
roles in human immunodeficiency virus type 1 envelope glycoprotein
interactions with the CCR5 coreceptor. J Virol. 2002;76:8953–7.
Fouchier RA, Groenink M, Kootstra NA, Tersmette M, Huisman HG,
Miedema F, Schuitemaker H. Phenotype-associated sequence variation in
the third variable domain of the human immunodeficiency virus type 1
gp120 molecule. J Virol. 1992;66:3183–7.
Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional
cDNA cloning of a seven-transmembrane, G protein-coupled receptor.
Science. 1996;272:872–7.
Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P,
Marmon S, Sutton RE, Hill CM, et al. Identification of a major co-receptor
for primary isolates of HIV-1. Nature. 1996;381:661–6.
Swanstrom R, Coffin J. HIV-1 pathogenesis: the virus. Cold Spring Harb
Perspect Med. 2012;2:a007443.
Gonzalez-Scarano F, Martin-Garcia J. The neuropathogenesis of AIDS. Nat
Rev Immunol. 2005;5:69–81.
Ochsenbauer C, Edmonds TG, Ding H, Keele BF, Decker J, Salazar MG,
Salazar-Gonzalez JF, Shattock R, Haynes BF, Shaw GM, et al. Generation of
transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocytederived macrophages. J Virol. 2012;86:2715–28.
Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG,
Sun C, Grayson T, Wang S, Li H, et al. Identification and characterization of
transmitted and early founder virus envelopes in primary HIV-1 infection.
Proc Natl Acad Sci USA. 2008;105:7552–7.
Sierra S, Kaiser R, Thielen A, Lengauer T. Genotypic coreceptor analysis.
Eur J Med Res. 2007;12:453–62.
Verhofstede C, Brudney D, Reynaerts J, Vaira D, Fransen K, De Bel A,
Seguin-Devaux C, De Wit S, Vandekerckhove L, Geretti AM. Concordance
between HIV-1 genotypic coreceptor tropism predictions based on
plasma RNA and proviral DNA. HIV Med. 2011;12:544–52.
Jensen MA, Li FS, van’t Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI. Improved coreceptor
usage prediction and genotypic monitoring of R5-to-X4 transition by
motif analysis of human immunodeficiency virus type 1 env V3 loop
sequences. J Virol. 2003;77:13376–88.
Aiamkitsumrit B, Dampier W, Antell G, Rivera N, Martin-Garcia J, Pirrone V,
Nonnemacher MR, Wigdahl B. Bioinformatic analysis of HIV-1 entry and
pathogenesis. Curr HIV Res. 2014;12:132–61.
Carrillo A, Ratner L. Cooperative effects of the human immunodeficiency
virus type 1 envelope variable loops V1 and V3 in mediating infectivity for
T cells. J Virol. 1996;70:1310–6.
Huang W, Toma J, Fransen S, Stawiski E, Reeves JD, Whitcomb JM, Parkin
N, Petropoulos CJ. Coreceptor tropism can be influenced by amino acid
substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol. 2008;82:5584–93.
Koito A, Stamatatos L, Cheng-Mayer C. Small amino acid sequence
changes within the V2 domain can affect the function of a T-cell linetropic human immunodeficiency virus type 1 envelope gp120. Virology.
1995;206:878–84.
Labrosse B, Treboute C, Brelot A, Alizon M. Cooperation of the V1/V2 and
V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor. J Virol. 2001;75:5457–64.
Pastore C, Nedellec R, Ramos A, Pontow S, Ratner L, Mosier DE. Human
immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness
mutations compensate for V3 loss-of-fitness mutations. J Virol. 2006;80:750–8.
Suphaphiphat P, Essex M, Lee TH. Mutations in the V3 stem versus the V3
crown and C4 region have different effects on the binding and fusion
steps of human immunodeficiency virus type 1 gp120 interaction with
the CCR5 coreceptor. Virology. 2007;360:182–90.
Thielen A, Sichtig N, Kaiser R, Lam J, Harrigan PR, Lengauer T. Improved
prediction of HIV-1 coreceptor usage with sequence information from
the second hypervariable loop of gp120. J Infect Dis. 2010;202:1435–43.
Dimonte S, Mercurio F, Svicher V, D’Arrigo R, Perno CF, Ceccherini-Silberstein F. Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v(3) signatures in the regulation of co-receptor
usage. Retrovirology. 2011;8:33.
Coetzer M, Nedellec R, Cilliers T, Meyers T, Morris L, Mosier DE. Extreme
genetic divergence is required for coreceptor switching in HIV-1 subtype
C. J Acquir Immune Defic Syndr. 2011;56:9–15.

Antell et al. Retrovirology (2016) 13:32

28. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson
WA. Structure of an HIV gp120 envelope glycoprotein in complex
with the CD4 receptor and a neutralizing human antibody. Nature.
1998;393:648–59.
29. Nonnemacher MR, Irish BP, Liu Y, Mauger D, Wigdahl B. Specific sequence
configurations of HIV-1 LTR G/C box array result in altered recruitment
of Sp isoforms and correlate with disease progression. J Neuroimmunol.
2004;157:39–47.
30. Roy S, Delling U, Chen CH, Rosen CA, Sonenberg N. A bulge structure in
HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation. Genes Dev. 1990;4:1365–73.
31. Sturdevant CB, Joseph SB, Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalized replication of R5 T cell-tropic HIV-1 in the
central nervous system early in the course of infection. PLoS Pathog.
2015;11:e1004720.
32. Yukl S, Pillai S, Li P, Chang K, Pasutti W, Ahlgren C, Havlir D, Strain M, Gunthard H, Richman D, et al. Latently-infected CD4 + T cells are enriched
for HIV-1 Tat variants with impaired transactivation activity. Virology.
2009;387:98–108.
33. Reza SM, Shen LM, Mukhopadhyay R, Rosetti M, Pe’ery T, Mathews MB. A
naturally occurring substitution in human immunodeficiency virus Tat
increases expression of the viral genome. J Virol. 2003;77:8602–6.
34. Selby MJ, Bain ES, Luciw PA, Peterlin BM. Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat
through the HIV-1 long terminal repeat. Genes Dev. 1989;3:547–58.
35. Sandelin A, Alkema W, Engstrom P, Wasserman WW, Lenhard B. JASPAR:
an open-access database for eukaryotic transcription factor binding
profiles. Nucleic Acids Res. 2004;32:D91–4.
36. Mathelier A, Zhao X, Zhang AW, Parcy F, Worsley-Hunt R, Arenillas DJ,
Buchman S, Chen CY, Chou A, Ienasescu H, et al. JASPAR 2014: an extensively expanded and updated open-access database of transcription
factor binding profiles. Nucleic Acids Res. 2014;42:D142–7.
37. McAllister JJ, Phillips D, Millhouse S, Conner J, Hogan T, Ross HL, Wigdahl
B. Analysis of the HIV-1 LTR NF-kappaB-proximal Sp site III: evidence
for cell type-specific gene regulation and viral replication. Virology.
2000;274:262–77.
38. Millhouse S, Krebs FC, Yao J, McAllister JJ, Conner J, Ross H, Wigdahl B. Sp1
and related factors fail to interact with the NF-kappaB-proximal G/C box
in the LTR of a replication competent, brain-derived strain of HIV-1 (YU-2).
J Neurovirol. 1998;4:312–23.
39. Palmieri C, Trimboli F, Puca A, Fiume G, Scala G, Quinto I. Inhibition
of HIV-1 replication in primary human monocytes by the IkappaBalphaS32/36A repressor of NF-kappaB. Retrovirology. 2004;1:45.
40. Rohr O, Sawaya BE, Lecestre D, Aunis D, Schaeffer E. Dopamine stimulates
expression of the human immunodeficiency virus type 1 via NF-kappaB
in cells of the immune system. Nucleic Acids Res. 1999;27:3291–9.

Page 14 of 14

41. Rohr O, Aunis D, Schaeffer E. COUP-TF and Sp1 interact and cooperate in the transcriptional activation of the human immunodeficiency
virus type 1 long terminal repeat in human microglial cells. J Biol Chem.
1997;272:31149–55.
42. Krebs FC, Goodenow MM, Wigdahl B. Neuroglial ATF/CREB factors interact with the human immunodeficiency virus type 1 long terminal repeat.
J Neurovirol. 1997;3(Suppl 1):S28–32.
43. Li L, Aiamkitsumrit B, Pirrone V, Nonnemacher MR, Wojno A, Passic S,
Flaig K, Kilareski E, Blakey B, Ku J, et al. Development of co-selected single
nucleotide polymorphisms in the viral promoter precedes the onset
of human immunodeficiency virus type 1-associated neurocognitive
impairment. J Neurovirol. 2011;17:92–109.
44. Parikh N, Dampier W, Feng R, Passic SR, Zhong W, Frantz B, Blakey B, Aiamkitsumrit B, Pirrone V, Nonnemacher MR, et al. Cocaine alters cytokine profiles
in HIV-1-infected African American individuals in the DrexelMed HIV/AIDS
genetic analysis cohort. J Acquir Immune Defic Syndr. 2014;66:256–64.
45. Aiamkitsumrit B, Dampier W, Martin-Garcia J, Nonnemacher MR, Pirrone V,
Ivanova T, Zhong W, Kilareski E, Aldigun H, Frantz B, et al. Defining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear
sequences. PLoS ONE. 2014;9:e107389.
46. Nonnemacher MR, Pirrone V, Feng R, Moldover B, Passic S, Aiamkitsumrit
B, Dampier W, Wojno A, Kilareski E, Blakey B, et al. HIV-1 promoter single
nucleotide polymorphisms are associated with clinical disease severity.
PLoS One. 2016;11:e0150835.
47. Aimkitsumrit BD, Dampier W, Martin-Garcia J, Nonnemacher M, Pirrone
V, Ivanova T, Zhong W, Kilareski E, Aldigun A, Frantz B, Rimbey M, Wojno
A, Passic S, Williams J, Shah S, Blakely B, Parikh N, Jacobson J, Moldover
B, Wigdahl B. Defining differential genetic signatures in CXCR4- and the
CCR5-utilizing HIV-1 co-linear sequences. PLoS One. 2014;29:e107389.
48. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5:
molecular evolutionary genetics analysis using maximum likelihood,
evolutionary distance, and maximum parsimony methods. Mol Biol Evol.
2011;28:2731–9.
49. Schwartz GW, Hershberg U. Conserved variation: identifying patterns of
stability and variability in BCR and TCR V genes with different diversity
and richness metrics. Phys Biol. 2013;10:035005.
50. Ashkenazy H, Erez E, Martz E, Pupko T, Ben-Tal N. ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and
nucleic acids. Nucleic Acids Res. 2010;38:W529–33.
51. Yona G, Levitt M. Within the twilight zone: a sensitive profile-profile comparison tool based on information theory. J Mol Biol. 2002;315:1257–75.
52. Wang G, Dunbrack RL Jr. Scoring profile-to-profile sequence alignments.
Protein Sci. 2004;13:1612–26.
53. Vacic V, Iakoucheva LM, Radivojac P. Two Sample Logo: a graphical representation of the differences between two sets of sequence alignments.
Bioinformatics. 2006;22:1536–7.

Submit your next manuscript to BioMed Central
and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit

